Novel combinations and uses of antibodies
JP2025507867A5Pending Publication Date: 2026-04-02BIOINVENT INT AB +1
View PDF 0 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2023-03-06
- Publication Date
- 2026-04-02
AI Technical Summary
Technical Problem
Current treatments for FcγRIIB-negative cancers, such as most solid cancers, do not effectively enhance the therapeutic activity of direct tumor target antibodies like anti-HER2 or anti-EGFR.
Method used
The use of a first antibody molecule that specifically binds to FcγRIIB via the Fab region and lacks the Fc region or has reduced binding to Fcγ receptors, in combination with a second antibody molecule that specifically binds to a receptor present on tumor cells and has an Fc region capable of activating at least one activated Fcγ receptor.
Benefits of technology
This combination enhances the therapeutic activity of tumor direct target antibodies, such as anti-HER2, even in cancers with low HER2 expression, by optimizing FcγR-dependent tumor cell killing.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 00000000_0000_ABST
Abstract
The present invention describes the use of a first antibody molecule that specifically binds to FcγRIIB via its Fab region but lacks an Fc region or has reduced binding to Fcγ receptors via the Fc region, for use in combination with a second antibody molecule that specifically binds to a receptor present on tumor cells, in the treatment of FcγRIIB-negative cancer in a patient, where the second antibody molecule has an Fc region that binds to at least one activating Fcγ receptor, as well as pharmaceutical compositions and kits comprising these two antibody molecules, and methods of treating cancer using these two antibodies.
Need to check novelty before this filing date? Find Prior Art